Rare cytotoxic T cells expand in centenarians, but their role in longevity remains unclear

What happened

A small human study published August 19 in *Cell Reports* found that an unusual population of immune cells became increasingly prominent across groups of older adults, centenarians and supercentenarians. The cells, known as cytotoxic CD4 T lymphocytes, were also dominated by expanded clones—a pattern consistent with an adaptive immune response to persistent targets.

Researchers analyzed blood from 28 Japanese adults divided into three age groups: 70–99, 100–109, and at least 110 years old. Cytotoxic CD4 T cells accounted for a median 4% of CD4 T cells in the youngest group, 9.6% among centenarians and 17.6% among supercentenarians.

The result adds detail to earlier reports that people surviving beyond 110 can carry unusually large cytotoxic CD4 populations. It does not establish that the cells enabled participants to reach extreme ages, protected them from cancer or represent a target for a longevity intervention.

Unusual cells with expanded families

Most CD4 T cells coordinate immune responses rather than directly kill target cells. Cytotoxic CD4 cells are different: they express molecular machinery associated with destroying infected, damaged or malignant cells. Their biological effects are context-dependent, however, and related populations have also been implicated in autoimmune and neurodegenerative disease.

The researchers combined single-cell RNA sequencing, cell-surface protein measurements and T-cell receptor sequencing. The receptor sequence acts as a molecular identifier for the antigen-recognition machinery carried by each T-cell clone.

Within each participant’s cytotoxic CD4 population, the largest clone represented an average 33.3% of the cells. In one centenarian, a single clone accounted for 53.8%. This concentration indicates that selected cells had multiplied extensively rather than the compartment expanding through many unrelated cells.

The team also compared receptor sequences with public databases. Nearly three dozen matches were associated with samples from people with lung, breast or liver cancer. None of the centenarians or supercentenarians had a known history of those cancers.

That comparison is intriguing but indirect. A matching receptor sequence does not by itself identify the antigen being recognized, demonstrate that a participant had an occult tumor, or show that the cells killed cancer cells. The investigators therefore described the cells as potentially responsive to cancer-related targets while acknowledging that their exact targets remain unknown.

What the design cannot resolve

This was a cross-sectional analysis of exceptionally old survivors, not a study that followed people from midlife to determine who lived longest. Survival selection is consequently central: people who reached 100 or 110 may differ from their birth cohorts in genetics, infection history, environment, healthcare and many other characteristics.

The age pattern was not absolute. One participant younger than 100 had the study’s highest proportion of cytotoxic CD4 cells. That individual variation, together with the sample of only 28 people from one country, limits generalization.

Blood also provides only a partial view of immunity. The study did not establish whether the expanded clones entered organs, recognized senescent or malignant cells in tissue, or improved clinical outcomes. Previous infections—particularly persistent viruses—could offer another explanation for clonal expansion.

Why it matters for aging research

Immune aging is often framed as progressive loss: fewer naïve T cells, weaker vaccine responses and increasing inflammatory dysfunction. These data support a more complicated model in which selected immune populations can continue adapting even at extreme ages.

The practical implication is a research question rather than a treatment conclusion. Longitudinal cohorts could determine whether cytotoxic CD4 expansion precedes exceptional survival or develops because of decades of accumulated immune exposures. Functional experiments will also be needed to identify the clones’ targets and determine whether their activity is protective, neutral or harmful in different tissues.

For now, the study offers a cellular signature associated with exceptional longevity—not an explanation for it.